Determination of Residual Anticoagulatory Effects of Fondaparinux

• Conditions: Anticoagulant Prophylaxis/Therapy

• Registration Number: NCT01101256
• Lead Sponsor: Johann Wolfgang Goethe University Hospital

Brief Summary

The purpose of this study is to determine residual anticoagulatory effects of a prophylactic or therapeutic fondaparinux treatment i.e. prior to surgery/intervention, after pause of therapy etc.

Detailed Description

Not available

Study Timeline

• Status Verified: 2010-04
• Study Start: 2010-04
• Study First Submitted: 2010-04-07
• Study First Submitted QC: 2010-04-08
• Study First Posted: 2010-04-09
• Last Update Submitted: 2010-04-12
• Last Update Posted: 2010-04-13
• Primary Completion: 2010-09
• Study Completion: 2010-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

• Fondaparinux therapy for at least 3 days

Exclusion Criteria

• Age < 18 years
• Hemodialysis

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
antiXa-levels (peak- and through-levels)	between day 3 and day 14 after start of therapy

Secondary Outcome Measures

Name	Time	Method
thromboembolic or bleeding episodes, HIT	day 14 after start of therapy

Trial Locations

Locations (1)

J.W. Goethe University Hospital Frankfurt/M.; 🇩🇪 Frankfurt am Main, Hessen, Germany